Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (DE:1VT)
NASDAQ:1VT
Earnings Data
Report Date
Apr 29, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.84Last Year’s EPS
-0.35Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized substantial clinical and operational progress: compelling Phase II efficacy for both subcutaneous (up to 14.7%) and oral (up to 12.2%, with 80% ≥10% responders), initiation and fast enrollment of Phase III programs, completion of auto-injector bioequivalence enabling device rollout, a completed maintenance study enrollment with results expected Q3 2026, a manufacturing agreement to support commercialization, and expansion of the pipeline with an amylin agonist. Offsetting these positives are sharply higher R&D expenses and widening net losses (large YoY increases), a ~22% decline in cash year-over-year, and a projected quarterly burn of $60M–$90M, alongside marketplace and reimbursement uncertainties. On balance, the operational and clinical milestones materially outweigh the financial and market risks presented on the call.Company Guidance
Robust Phase II Efficacy — Subcutaneous VK2735
Phase II VENTURE subcutaneous results showed statistically significant weight loss up to 14.7% after 13 weekly doses; Phase I subcutaneous cohorts showed up to ~8% weight loss after 4 weekly doses. Safety/tolerability described as encouraging with most adverse events mild or moderate.
Strong Oral Phase II Results
VENTURE-Oral topline results: once-daily oral VK2735 produced up to 12.2% mean weight loss after 13 weeks. Statistically significant differences vs placebo observed from week 1 for doses >15 mg. Up to 80% of subjects on VK2735 achieved ≥10% weight loss vs 5% for placebo.
Phase III Programs Initiated and Enrollment Progress
Initiated VANQUISH Phase III program (two trials: VANQUISH-1 for obesity, VANQUISH-2 for obesity + T2D). VANQUISH-1 fully enrolled ahead of schedule and exceeded the planned ~4,500 patient target; VANQUISH-2 (target ~1,100) is nearing completion.
Oral VK2735 Planned for Phase III
Following positive oral Phase II and an end-of-Phase II meeting with FDA, company plans to initiate oral VK2735 Phase III in Q3 2026, with expectations of shorter/leaner trial design vs VANQUISH (reduced duration/size/visit intensity possible).
Maintenance Dosing Study Launched and Enrolled
Phase I maintenance dosing study completed enrollment in January 2026; evaluates multiple regimens (monthly, every-other-week, weekly subcutaneous; weekly and daily oral) after 19 weeks of initial weekly dosing. Results expected in Q3 2026.
Commercial and Manufacturing Preparation
Signed comprehensive manufacturing and supply agreement with CordenPharma covering large-scale API and fill/finish for both subcutaneous and oral formulations (company indicates capacity to support a multibillion-dollar opportunity). Appointed Neil Aubuchon as Chief Commercial Officer to lead commercial strategy.
Pipeline Expansion — Amylin Agonist Program
Advanced amylin receptor agonist program with IND expected later this quarter; first-in-human dosing likely in Q2 2026 and potential Phase I data later in 2026, adding a differentiated mechanism to the obesity portfolio.
Solid Cash Position with Explicit Runway Commentary
Cash, cash equivalents and short-term investments of $706M at Dec 31, 2025. Management states this balance is sufficient to support key upcoming milestones (maintenance study, Phase III subcutaneous readouts and oral Phase III top-line data).
DE:1VT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:1VT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | €23.39 | €26.97 | +15.31% |
Oct 22, 2025 | €27.89 | €29.99 | +7.51% |
Jul 24, 2025 | €29.12 | €29.10 | -0.07% |
Apr 23, 2025 | €21.82 | €22.01 | +0.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Viking Therapeutics (DE:1VT) report earnings?
Viking Therapeutics (DE:1VT) is schdueled to report earning on Apr 29, 2026, After Close (Confirmed).
What is Viking Therapeutics (DE:1VT) earnings time?
Viking Therapeutics (DE:1VT) earnings time is at Apr 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Viking Therapeutics stock?
The P/E ratio of Viking Therapeutics is N/A.
What is DE:1VT EPS forecast?
DE:1VT EPS forecast for the fiscal quarter 2026 (Q1) is -0.84.